The FDA is reviewing the condition of omeprazole (Prilosec, AstraZeneca) and esomeprazole (Nexium, AstraZeneca), proton-pump inhibitors used for the communicating of gastroesophageal flow disease (GERD) and ulcers, based on analyses from two clinical trials suggesting the drugs may gain cardiovascular risk, the way announced 24-hour interval .
But because of questions about the clinical-trial data and their mutual exclusiveness with a large total of other data screening no such increased risks, the "FDA does not believe that healthcare providers or patients should coin either their prescribing practices or their use of these products at this time," according to an "Early Communication" posted on the agency's website.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment